Early Launch Metrics Reveal an Impressive Start for Sanofi/Regeneron’s Dupixent in Eosinophilic Esophagitis, According to Recent Research Conducted by Spherix Global Insights
Despite satisfaction among gastroenterologists and allergists who have trialed the drug, high patient out-of-pocket costs and reimbursement hassles could hamper